BioInnovation Institute (BII), a Novo Nordisk Basis Initiative, has offered a further €1.3 million in follow-on funding to 5 portfolio startups – Synuca Therapeutics, Gefjon Pharma, MicroMiner, DARERL and Diasense – bringing the whole help for every firm to €1.8 million.
These 5 startups are actually getting into BII’s ‘Enterprise Home 8’ cohort. The funding is geared toward serving to the startups speed up product improvement, scale operations, and transfer nearer to market deployment throughout sectors spanning HealthTech, AgriTech, ClimateTech and DeepTech.
This comes one month after BII introduced it had secured €25 million in Novo Nordisk Basis funding, as covered by EU-Startups.
“These 5 corporations embody what BII stands for – turning sturdy science into options that make an actual distinction for folks and society. By our Enterprise Home program, we look ahead to supporting their subsequent steps towards funding and bringing their applied sciences to market,” shared BII’s Chief Enterprise Officer, Trine Bartholdy with EU-Startups.
Latest exercise in 2025–2026 reveals comparable albeit bigger capital swimming pools being mobilised throughout Europe that assist contextualise right now’s funding from BII.
Paris-based Ventech closed a €175 million sixth fund to again utilized AI and vitality transition startups, whereas Serena reached a €200 million first shut for Fund IV with the same utilized AI and local weather focus. London-based Evantic Capital launched a €341 million debut automobile concentrating on B2B AI throughout Europe, the US and Israel. In Germany, Vanagon Ventures secured €20 million for pre-seed deep tech and AI investments, whereas earlier studies additionally referenced rising managers reminiscent of Might Ventures (Germany) and Masia (Spain) with funds exceeding €30 million and €20 million respectively.
Collectively, these VC fund bulletins signify roughly €780 million in newly raised capital directed in direction of European expertise sectors together with AI, DeepTech and vitality transition.
Not one of the cited autos are Denmark-based, underscoring BII’s function inside their ecosystem to help innovation at earlier, research-translation levels.
Based in 2018, BII gives life science researcher and entrepreneurs entry to a life science neighborhood with 3500 sq. meter of superior lab and workplace services, enterprise acceleration programmes, industrial help, funding alternatives and entry to mentoring and networks.
These 5 corporations inside BII’s portfolio had beforehand acquired €500k from BII and can now use the brand new capital injection to advance vital milestones, from lead optimisation in neurodegenerative illness analysis to scaling vaccine manufacturing and industrialising quantum diagnostics instruments.
BII is offering the capital as a part of its broader mission to translate cutting-edge analysis into commercially viable options with societal influence.
The 5 startups:
- Synuca Therapeutics, based in 2025 in Aarhus, is the primary firm to be funded via BII’s €42 million (320 million DKK) innovation partnership with Lundbeckfonden / Lundbeck Basis. The startup is growing a disease-modifying remedy for sufferers affected by Parkinson’s Illness and related mind problems. Constructed on a long time of analysis in P-type ATPases and neuroscience from Aarhus College, Synuca Therapeutics is concentrating on the SERCA calcium transporter with small molecules designed to restore neuronal calcium imbalances brought on by pathological α-Synuclein mind species. With the brand new funding, the corporate plans to speed up lead optimisation and deepen mechanistic understanding in preparation for additional preclinical improvement.
- Gefjon Pharma, based in Copenhagen in 2023, is targeted on lowering antimicrobial use in livestock manufacturing. The corporate has developed a platform primarily based on its hyper vesiculating outer membrane vesicle (OMV) expertise, mixed with a proprietary extraction technique that allows high-yield, cost-effective manufacturing of bio-industrials and therapeutics. Its first product is a broad-protective bacterial E. coli vaccine concentrating on poultry manufacturing, with proof of idea demonstrated each for the vaccine and for an aerosol software technique. As E. coli stays a number one explanation for mortality and an infection in poultry, the corporate goals to scale back world antimicrobial consumption, restrict the event of antimicrobial resistance, and enhance animal welfare. The extra funding will help market entry and scale-up of manufacturing.
- MicroMiner, based in Copenhagen, is growing biotechnology options to enhance the sustainability of electrical automobile batteries. The corporate focuses on extracting and recycling vital metals from EV battery supplies via superior bioprocessing methods and partnerships throughout the battery worth chain. Its BioMagnetics™ adsorbents allow customisable steel selectivity utilizing organic mechanisms, whereas being designed for harsh industrial circumstances and containing no stay cells, which simplifies integration into present processes. With the brand new capital, MicroMiner plans to transition farther from laboratory science to deployable industrial expertise.
- DARERL, based in Copenhagen in 2024, offers a SaaS platform for early-stage testing and improvement of medical units and wearables. The corporate generates digital human fashions instantly from medical pictures of actual people, enabling units to be simulated and examined in anatomically reasonable digital environments. By providing detailed inspection contained in the human physique and entry to population-level anatomical variability, DARERL goals to scale back reliance on animal research, cadavers and in depth bench testing. The extra funding will assist speed up the shift in direction of simulation-driven improvement and broaden the capabilities of its digital anatomy platform.
- Diasense, based in Copenhagen in 2024, is industrialising a quantum diamond magnetic microscope designed to ship real-time diagnostics and course of insights for next-generation semiconductor fabrication. Its expertise allows contactless chip failure evaluation at microscopic decision and excessive sensitivity, uncovering failure mechanisms that stay invisible to conventional methods. The corporate’s rapid focus is on scaling the platform and getting ready it for deployment in high-volume manufacturing environments.
The follow-on funding from BII underlines a continued dedication to nurturing research-driven startups at vital inflection factors.
“Enterprise Home offers not solely capital, however a platform for disciplined execution and strategic improvement. The programme allows us to additional mature our science, sharpen our improvement path, and proceed constructing a crew able to translating first-in-class biology right into a clinical-stage therapeutic alternative,” stated Synuca Therapeutics in a public assertion.
By supporting corporations engaged on neurological therapies, sustainable agriculture, battery recycling, digital medical simulation and semiconductor diagnostics, BII is reinforcing its function inside Denmark in bridging the hole between educational discovery and industrial software throughout a number of high-impact sectors.
